Drugs / Bendamustin

Trials 6 · a red edge is where a trial was stopped

2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT01078142 Feb 2010 → Sep 2017 follicular lymphoma, mantle cell lymphoma Georg Hess, MD Completed No outcome recorded
Phase 25 trials
Phase 2 NCT06136351 Nov 2023 → Nov 2027 expected mantle cell lymphoma Ruijin Hospital Recruiting No outcome recorded
Phase 2 NCT05918276 Jul 2023 → Dec 2024 overdue chronic lymphocytic leukemia/small lymphocytic lymphoma Nanfang Hospital, Southern Medical University Not yet recruiting No outcome recorded
Phase 2 NCT04934930 Jan 2020 → Aug 2025 follicular lymphoma Meir Medical Center Unknown No outcome recorded
Phase 2 NCT00204620 Mar 2002 → Dec 2006 soft tissue sarcoma University Hospital Tuebingen Completed No outcome recorded
Phase 2 NCT00168922 Feb 2001 → Dec 2006 small cell lung carcinoma Charite University, Berlin, Germany Unknown No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07575893 Background Oct 2026 → Dec 2031 expected classic Hodgkin lymphoma New York Medical College Not yet recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT06284122 Comparator Jun 2024 → Nov 2028 expected follicular lymphoma The Lymphoma Academic Research Organisation Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Bendamustin “Drug: BG Bendamustin 70mg/m2, IV, d2\&d3 inC1, and then d1\&d2 inC2-6.” NCT05918276
7

NCT00168922

NCT06136351

NCT06284122

NCT01078142

NCT00204620

NCT07575893

NCT04934930

Known as Ribomustin “Bendamustin/RibomustinNCT00168922
Route Intravenous “Bendamustin 70mg/m2, IV, d2\&d3 inC1, and then d1\&d2 inC2-6.” NCT05918276